4/16
1.3 / 5 stars
All 16 Win/Lose results and 104 gray no-data contests shown below
SOLV Roast Me summary
Solventum Corp (SOLV). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return No data; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return No data; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return No data; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return No data; Revenue growth Lose; EPS growth Win.
Trailing 1 year (4 quarters): 4 wins, 4 losses, 4 no dataLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
No dataSOLV / S&P / 15.20% |
LoseSOLV / S&P -0.93% / 15.00% |
WinSOLV / S&P 276.50% / 50.40% |
| 2026-Q11/2 |
No dataSOLV / S&P / -4.33% |
LoseSOLV / S&P -0.55% / 11.30% |
WinSOLV / S&P 275.58% / 27.70% |
| 2025-Q41/2 |
No dataSOLV / S&P / 2.65% |
LoseSOLV / S&P 0.86% / 9.00% |
WinSOLV / S&P 221.74% / 13.40% |
| 2025-Q31/2 |
No dataSOLV / S&P / 8.12% |
LoseSOLV / S&P 2.28% / 4.61% |
WinSOLV / S&P 109.40% / 13.45% |
| 2025-Q20/2 |
No dataSOLV / S&P / 10.94% |
LoseSOLV / S&P 2.21% / 4.83% |
LoseSOLV / S&P -64.48% / 10.63% |
| 2025-Q10/2 |
No dataSOLV / S&P / -4.27% |
LoseSOLV / S&P 1.29% / 4.98% |
LoseSOLV / S&P -70.91% / 10.57% |
| 2024-Q40/2 |
No dataSOLV / S&P / 2.41% |
LoseSOLV / S&P 0.70% / 5.25% |
LoseSOLV / S&P -64.57% / 6.15% |
| 2024-Q30/0 |
No dataSOLV / S&P / 5.89% |
No dataSOLV / S&P / 5.89% |
No dataSOLV / S&P / 6.11% |
| 2024-Q20/0 |
No dataSOLV / S&P / 4.28% |
No dataSOLV / S&P / 5.38% |
No dataSOLV / S&P / 5.12% |
| 2024-Q10/0 |
No dataSOLV / S&P / 10.56% |
No dataSOLV / S&P / 5.71% |
No dataSOLV / S&P / 5.59% |
| 2023-Q40/2 |
No dataSOLV / S&P / 11.69% |
LoseSOLV / S&P 0.82% / 6.81% |
LoseSOLV / S&P 0.13% / 7.78% |
| 2023-Q30/0 |
No dataSOLV / S&P / -3.27% |
No dataSOLV / S&P / 7.52% |
No dataSOLV / S&P / -5.03% |
| 2023-Q20/0 |
No dataSOLV / S&P / 8.74% |
No dataSOLV / S&P / 9.50% |
No dataSOLV / S&P / -8.57% |
| 2023-Q10/0 |
No dataSOLV / S&P / 7.50% |
No dataSOLV / S&P / 10.77% |
No dataSOLV / S&P / -15.69% |
| 2022-Q40/0 |
No dataSOLV / S&P / 7.56% |
No dataSOLV / S&P / 11.88% |
No dataSOLV / S&P / -17.99% |
| 2022-Q30/0 |
No dataSOLV / S&P / -4.88% |
No dataSOLV / S&P / 13.47% |
No dataSOLV / S&P / -1.41% |
| 2022-Q20/0 |
No dataSOLV / S&P / -16.10% |
No dataSOLV / S&P / 13.71% |
No dataSOLV / S&P / 11.04% |
| 2022-Q10/0 |
No dataSOLV / S&P / -4.60% |
No dataSOLV / S&P / 15.97% |
No dataSOLV / S&P / 42.23% |
| 2021-Q40/0 |
No dataSOLV / S&P / 11.03% |
No dataSOLV / S&P / 15.00% |
No dataSOLV / S&P / 96.40% |
| 2021-Q30/0 |
No dataSOLV / S&P / 0.58% |
No dataSOLV / S&P / 10.77% |
No dataSOLV / S&P / 69.42% |
| 2021-Q20/0 |
No dataSOLV / S&P / 8.55% |
No dataSOLV / S&P / 6.58% |
No dataSOLV / S&P / 51.81% |
| 2021-Q10/0 |
No dataSOLV / S&P / 6.17% |
No dataSOLV / S&P / -1.06% |
No dataSOLV / S&P / 7.39% |
| 2020-Q40/0 |
No dataSOLV / S&P / 12.15% |
No dataSOLV / S&P / -3.72% |
No dataSOLV / S&P / -33.42% |
| 2020-Q30/0 |
No dataSOLV / S&P / 8.93% |
No dataSOLV / S&P / -2.04% |
No dataSOLV / S&P / -27.10% |
| 2020-Q20/0 |
No dataSOLV / S&P / 20.54% |
No dataSOLV / S&P / -0.46% |
No dataSOLV / S&P / -27.11% |
| 2020-Q10/0 |
No dataSOLV / S&P / -19.60% |
No dataSOLV / S&P / 3.47% |
No dataSOLV / S&P / -14.75% |
| 2019-Q40/0 |
No dataSOLV / S&P / 9.07% |
No dataSOLV / S&P / 5.36% |
No dataSOLV / S&P / 2.99% |
| 2019-Q30/0 |
No dataSOLV / S&P / 1.70% |
No dataSOLV / S&P / 5.02% |
No dataSOLV / S&P / 0.21% |
| 2019-Q20/0 |
No dataSOLV / S&P / 4.30% |
No dataSOLV / S&P / 6.64% |
No dataSOLV / S&P / 8.65% |
| 2019-Q10/0 |
No dataSOLV / S&P / 13.65% |
No dataSOLV / S&P / 8.12% |
No dataSOLV / S&P / 14.29% |
| 2018-Q40/0 |
No dataSOLV / S&P / -13.52% |
No dataSOLV / S&P / 9.05% |
No dataSOLV / S&P / 18.23% |
| 2018-Q30/0 |
No dataSOLV / S&P / 7.71% |
No dataSOLV / S&P / 10.21% |
No dataSOLV / S&P / 19.06% |
| 2018-Q20/0 |
No dataSOLV / S&P / 3.43% |
No dataSOLV / S&P / 9.03% |
No dataSOLV / S&P / 14.46% |
| 2018-Q10/0 |
No dataSOLV / S&P / -0.76% |
No dataSOLV / S&P / 7.68% |
No dataSOLV / S&P / 12.46% |
| 2017-Q40/0 |
No dataSOLV / S&P / 6.64% |
No dataSOLV / S&P / 7.03% |
No dataSOLV / S&P / 13.82% |
| 2017-Q30/0 |
No dataSOLV / S&P / 4.48% |
No dataSOLV / S&P / 5.68% |
No dataSOLV / S&P / 17.57% |
| 2017-Q20/0 |
No dataSOLV / S&P / 3.09% |
No dataSOLV / S&P / 4.83% |
No dataSOLV / S&P / 17.74% |
| 2017-Q10/0 |
No dataSOLV / S&P / 6.07% |
No dataSOLV / S&P / 3.67% |
No dataSOLV / S&P / 13.32% |
| 2016-Q40/0 |
No dataSOLV / S&P / 3.82% |
No dataSOLV / S&P / 2.09% |
No dataSOLV / S&P / 7.05% |
| 2016-Q30/0 |
No dataSOLV / S&P / 3.85% |
No dataSOLV / S&P / 0.20% |
No dataSOLV / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |